Below are the latest news stories about Dyne Therapeutics Inc that investors may wish to consider to help them evaluate DYN as an investment opportunity.
Dyne Therapeutics (DYN) has priced its public offering of 6M common shares at $28.00/share, for expected gross proceeds of ~$168M.Underwriters' over-allotment is an additional 900K shares.Closing date is January 25.... Seeking Alpha | January 21, 2021 |
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $28.00 per share. In addition, Dyne has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price, less the underwriting discount and commissions. All of the shares are being offered by Dyne. The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Dyne, are expected to be approximatel... Yahoo | January 21, 2021 |
\- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -\- Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 -WALTHAM, Mass., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data from its myotonic dystrophy type 1 (DM1) program demonstrating robust RNA knockdown of toxic human nuclear DMPK, the genetic basis of the disease.Dyne’s FORCE™ platform leverages the importance of transferrin 1 receptor, TfR1, in muscle biology as the foundation for its novel approach. TfR1, which is hi... Yahoo | January 10, 2021 |
WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/investors-and-media and a replay will be accessible for 90 days following the presentation.About Dyne TherapeuticsDyne Therapeutics is building a leading muscle disease company focused... Yahoo | January 5, 2021 |
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual investor conferences. Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, will participate in fireside chats at the following: * Stifel 2020 Virtual Healthcare Conference; Monday, November 16, 2020 at 10:00 a.m. ET * Jefferies Virtual London Healthcare Conference; Thursday, November 19, 2020 at 7:55 a.m. ET * Piper Sandler 32nd Annual Virtual Healthcare Conference; pre-recorded and expected to be available Monday, November 23, 2020 Webc... Yahoo | November 9, 2020 |
Loading social stream, please wait...